Crinetics
3 known investors
Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.
Biotech
Investors · 3
Non-dilutive funding · 11 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $299.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $297.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $326.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $224.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $2.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $296.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $282.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $237.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Crinetics do?
- Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.
- Who are Crinetics's investors?
- Crinetics's investors include 5AM Ventures, OrbiMed, RA Capital.